Shionogi & Co., Ltd. (SGIOF)
Shionogi & Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Osaka, OS, JP. The stock last traded at $17.90, up 0.00% on the session, giving a market capitalisation of $15.23B. On trailing twelve-month figures it carries a trailing P/E of 9.11, a net margin of 46.8%. Its beta of 0.03 implies it has historically moved less than the broad market.
Shionogi & Co., Ltd. is a Japanese enterprise focused on the entire lifecycle of pharmaceutical products, diagnostic tools, and medical equipment, encompassing their investigation, creation, production, and supply within Japan. The company's marketed portfolio includes Fetroja, a therapy for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral medication targeting influenza; and Tivicay, which is used in HIV management. Shionogi actively pursues the development of numerous compounds addressing a wide array of medical conditions. Its investigational pipeline features treatments for opioid-induced constipation (Symproic); inflammatory pain (S-120083); neuropathic pain (S-010887, sivopixant, and S-637880 for low back pain); insomnia (S-117957); and central nervous system disorders such as sleep apnea syndrome, refractory/unexplained chronic cough (both sivopixant), depression (Zuranolone), and attention-deficit/hyperactivity disorder (SDT-001). The company also has candidates for Fragile X syndrome and Alzheimer's disease (BPN14770), as well as obesity (S-237648, S-309309). Its robust research pipeline further extends to treatments for conditions including decompensated liver cirrhosis (ADR-001) and NASH (S-723595). In oncology, Shionogi is advancing S-588410 for esophageal and bladder cancers, S-488210 for head and neck squamous cell carcinoma, and S-588210, S-222611, and S-531011 for various solid tumors and malignancies. Other investigational therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. The company is also heavily invested in COVID-19 therapeutics, with S-600918, S-217622, and S-555739 aimed at treating the virus and managing its worsening effects. Additionally, Shionogi provides diagnostic antibody test kits specifically for COVID-19. Shionogi & Co., Ltd. collaborates with academic and research institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University on joint initiatives, particularly in the development of antimalarial medications. Founded in Osaka, Japan, in 1878, the organization initially operated under the name Shionogi Shoten Co., Ltd. before adopting its current corporate identity, Shionogi & Co., Ltd., in 1943.
Shionogi & Co., Ltd. is most often compared with the following Healthcare names: